JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: Recently, combination therapies such as the dual-targeting of the Bcr-Abl and JAK2 activities have been shown to lead to more effective disease eradication, particularly for CML patients at high risk for TKI resistance and disease progression [19,20].